The Fist Derek Walcott’s 'The Fist' grips the heart in a brief, searing meditation on love, obsession, and survival at the edge of reason.

#DerekWalcott #TheFist #PoetryCommunity #PoemOfTheDay #PoemsRethabileLikes

Walcott was #poet and #playwright. He fused #Caribbean history & myth with classical forms. His #Omeros confirmed his stature, and he got the 1992 Nobel Prize in Literature.

The Fist po-re-li.blogspot.com/2026/03/the-...

Cover of Omeros by Derek Walcott for the Tuesday Book Club by P-Wave Press

Our first #TuesdayBookClub of 2026 is Omeros by Derek Walcott. An epic poem that drew me in slowly, then completely—revealing how history lives on in people, places, and the sea itself. A remarkable way to begin the year. 📚🌊 #Omeros #DerekWalcott #booksky
p-wavepress.co.uk/blog/files/t...

Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA

Novo builds pipeline again with $2.1bn Omeros deal Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders

#NovoNordisk has boosted its pipeline by paying $340m upfront for rights to an #Omeros drug for PNH and other rare blood and kidney disorders.

pharmaphorum.com/news/novo-bu...

Omeros stock rises after $22 million registered direct offering Investing.com -- Omeros Corporation (NASDAQ:OMER) stock rose 2.8% after the company announced it had entered into a securities purchase agreement with Polar Asset Management Partners for a $22 million registered direct offering. The agreement, announced on July 24, 2025, involves selling 5,365,853 shares of common stock at $4.10 per share, representing a 14% premium to the company’s closing price on the day of the agreement. The transaction is expected to close around July 28, 2025, subject to customary closing conditions. D. Boral (OTC:BOALY) Capital LLC is serving as the exclusive placement agent for the offering, which is being made through a "shelf" Registration Statement on Form S-3 previously filed with the SEC and declared effective on November 17, 2022. The company plans to issue a prospectus supplement detailing the terms of the public offering, which will form part of the effective registration statement. Omeros noted that the gross proceeds of approximately $22 million will be subject to deductions for placement agent fees and other offering expenses. The registered direct offering comes at a premium to the company’s recent trading price, which may have contributed to the positive market reaction reflected in today’s stock movement. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Omeros #StockMarket #Investing #FinanceNews #StockTrading

Omeros Corporation - Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.

Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros

Omeros Corporation - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.

Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: investor.omeros.com/news-release... #narsoplimab #complementinhibitor #omeros

Is #OMER worth buying? #Omeros #stocks #growthshares